Evidence map›Paper›PMID 40422017›Full record

ArticleBiosensors2025

Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars.

Andrea Di Santo, Edoardo Marrani, Carmen Gallo, Fosca Errante, Valerio Maniscalco, Anna Maria Papini, Gabriele Simonini, Paolo Rovero, Feliciana Real Fernandez

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrea Di SantoInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology (Peptlab), University of Florence, 50019 Sesto Fiorentino, Italy.ORCID 0000-0003-3075-8878
Edoardo MarraniRheumatology Unit, ERN ReCONNET Center, Meyer Children's Hospital IRCCS, 50139 Firenze, Italy.ORCID 0000-0002-0346-3268
Carmen GalloInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology (Peptlab), University of Florence, 50019 Sesto Fiorentino, Italy.
Fosca ErranteInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology (Peptlab), University of Florence, 50019 Sesto Fiorentino, Italy.ORCID 0000-0001-7790-9886
Valerio ManiscalcoRheumatology Unit, ERN ReCONNET Center, Meyer Children's Hospital IRCCS, 50139 Firenze, Italy.
Anna Maria PapiniInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology (Peptlab), University of Florence, 50019 Sesto Fiorentino, Italy.ORCID 0000-0002-2947-7107
Gabriele SimoniniDepartment of Neurosciences, Psychology, Drug Research and Child Health (NeuroFarBa), University of Florence, 50019 Sesto Fiorentino, Italy.ORCID 0000-0002-5919-4861
Paolo RoveroInterdepartmental Research Unit of Peptide and Protein Chemistry and Biology (Peptlab), University of Florence, 50019 Sesto Fiorentino, Italy.ORCID 0000-0001-9577-5228
Feliciana Real FernandezInstitute of Chemistry of Organometallic Compounds, National Research Council (ICCOM-CNR), 50019 Sesto Fiorentino, Italy.ORCID 0000-0001-5747-2285

Funding

European Union - Next Generation EU, PNRR MUR M4 C2 Inv. 1.5 of the National Recovery and Resilience Plan (PNRR) project ECS00000017 Tuscany-Health Ecosystem-Spoke6-CUP B63C2200068007
6 · The paper itself

Abstract

The use of adalimumab biosimilars has become increasingly common in clinical practice, reflecting their growing acceptance and efficacy as therapeutic alternatives to reference biologics. However, studies investigating the molecular interactions between anti-adalimumab antibodies (AAA) elicited in patients and different adalimumab biosimilars remain limited. This study aims to characterize the kinetic interactions between purified AAA from pediatric patients with Juvenile Idiopathic Arthritis and three adalimumab formulations: the originator Humira

Indexed as

AdalimumabAntibodiesArthritis, JuvenileBiosimilar PharmaceuticalsChildHumansKineticsSurface Plasmon ResonanceAdalimumabAntibodiesBiosimilar Pharmaceuticalsadalimumabanti-drug antibodiesbiosimilarsjuvenile idiopathic arthritissurface plasmon resonance

Identifiers

PMID40422017
PMCPMC12110412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.